June 2014 | Oncology & Biotech News

July 18, 2014

An early study presented at the 2014 AACR Annual Meeting showed promise for a new targeted therapy for acute myeloid leukemia

July 16, 2014

The 2nd Annual Giants of Cancer Careâ„¢ Awards were presented at a ceremony held on May 30 in Chicago. The event recognized 16 oncology heroes whose groundbreaking contributions to the field have improved the lives of patients with cancer.

July 07, 2014

Dacomitinib holds promise for the treatment of metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN).

July 02, 2014

Preliminary evidence supports the use of bromodomain inhibitors in hematologic malignancies, including acute leukemia (mainly acute myelogenous leukemia) and other hematological malignancies, including diffuse large B-cell lymphoma and multiple myeloma.

June 30, 2014

Every patient with a rare but aggressive form of ovarian cancer had tumors with the same type of mutations, suggesting a causative role for the mutations.

June 24, 2014

Genetic testing limited to BRCA1/2 mutations would have missed 29% of mutations that carry hereditary risk of ovarian cancer, a study using next-generation sequencing showed.

June 23, 2014

One-quarter of patients with relapsed or refractory BRCA-mutant ovarian cancer attained major objective responses to treatment with the investigational PARP inhibitor veliparib.

June 23, 2014

It may be possible to predict which men with metastatic castration-resistant prostate cancer will not respond to enzalutamide by using a simple blood test to detect the presence of AR-V7 in circulating tumor cells.

June 19, 2014

The measurement of response to anticancer therapy has evolved over the years as a result of better therapies and progress in imaging.

June 19, 2014

An MRI-guided focused ultrasound approach using heat to alleviate the pain commonly associated with bone metastases has proven to be safe and effective in a multi-center phase III clinical trial, yielding a 64% response rate.